Janssen, part of Johnson & Johnson (J&J, US), has announced the opening of a special emerging-market business unit. This will unite the company's various access models under one group and bring what J&J terms as "innovative pricing" and "results-based financing models" to emerging markets. In addition to pricing and access, J&J will also seek to design, develop or tailor products towards emerging-markets needs and launch projects including the development of Sirturo (bedaquiline), long-acting rilpivirine, dapivirine microbicidal ring, developing reformulated versions of flubendazole and mebendazole, as well as participation in the UNITE project (a collaboration of research partners on HIV research).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
157.4 USD | +4.20% |
|
+4.94% | +0.05% |
07:28pm | Fed Governor Waller's Comments, Earnings Leave Equities Mixed; Nvidia Slides | MT |
06:49pm | Megacap tech, chip stock rout drags Nasdaq to two-week low; Dow outperforms | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.05% | 363B | |
+56.99% | 848B | |
+31.64% | 627B | |
+15.45% | 318B | |
+12.68% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.56% | 179B | |
+3.47% | 167B | |
+2.52% | 125B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Launches Developing-World Business Unit